Y-mAbs Therapeutics (NASDAQ:YMAB) Raised to Hold at Wall Street Zen

Key Points

• Y-mAbs Therapeutics has been upgraded to a "hold" rating by Wall Street Zen, following downgrades from several other analysts who lowered price targets to $8.60.
• The stock currently has a consensus rating of "Reduce" with an average price target of $9.62, reflecting overall cautious sentiment among analysts.
• Despite recent struggles, Y-mAbs Therapeutics reported a quarterly earnings per share of ($0.07), exceeding analysts' estimates, and generated $19.52 million in revenue.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "hold" rating in a research note issued on Saturday.

YMAB has been the subject of a number of other research reports. Brookline Capital Management downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. HC Wainwright reiterated a "neutral" rating and issued a $8.60 target price (down previously from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th. Jones Trading cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Canaccord Genuity Group cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $26.00 to $8.60 in a report on Tuesday, August 5th. Finally, Oppenheimer cut Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 5th. Eight research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $9.62.

Y-mAbs Therapeutics Price Performance

YMAB stock remained flat at $8.61 during midday trading on Friday. The stock has a market capitalization of $391.24 million, a price-to-earnings ratio of -17.22 and a beta of 0.54. The business has a 50 day simple moving average of $7.27 and a 200 day simple moving average of $5.49. Y-mAbs Therapeutics has a 52-week low of $3.55 and a 52-week high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.20. The business had revenue of $19.52 million during the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%. Sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC grew its holdings in Y-mAbs Therapeutics by 223.9% during the first quarter. Cubist Systematic Strategies LLC now owns 155,522 shares of the company's stock worth $689,000 after buying an additional 107,511 shares in the last quarter. Bank of America Corp DE grew its stake in Y-mAbs Therapeutics by 59.5% in the 4th quarter. Bank of America Corp DE now owns 127,159 shares of the company's stock valued at $996,000 after purchasing an additional 47,439 shares during the period. Exchange Traded Concepts LLC grew its stake in Y-mAbs Therapeutics by 107.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock valued at $119,000 after purchasing an additional 13,890 shares during the period. Nuveen LLC bought a new position in Y-mAbs Therapeutics in the 1st quarter valued at $498,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Y-mAbs Therapeutics by 58.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company's stock valued at $1,052,000 after purchasing an additional 87,830 shares during the period. Institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.